{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:05:56Z","timestamp":1787162756091,"version":"build-2736575974"},"reference-count":25,"publisher":"Becaris Publishing Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Diabetic foot ulcers (DFUs) are often hard to heal and may require advanced treatment with cellular, acellular and matrix-like products (CAMPs). This retrospective cohort study examines the Medicare fee-for-service population to compare clinical outcomes and health resources utilization in patients receiving porcine placental extracellular matrix (PPECM [InnovaMatrix\n                    <jats:sup>\u00ae<\/jats:sup>\n                    AC, Convatec Triad Life Sciences, LLC, TN, USA]) against other CAMPs.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    The Center for Medicare &amp; Medicaid Services 100% Research Identifiable Files database was searched for potentially eligible patients using relevant ICD-10 diagnosis codes between 1 January 2020 and 31 December 2023. Patients with confirmed diagnoses of DFU and non-pressure chronic ulcers were selected for further evaluation. Eligible patients were categorized into groups according to treatment received: PPECM, PPECM\u2019s 510(k) predicate\u2020 (OASIS\n                    <jats:sup>\u00ae<\/jats:sup>\n                    Wound Matrix, Cook Biotech Inc., IN, USA), or other similar CAMPs (OSC [Marigen Shield and Omega3 (Kerecis, \u00cdsafj\u00f6r\u00f0ur, Iceland); Integra Dermal Regeneration Template and Primatrix (Integra LifeSciences, NJ, USA); GraftJacket (Stryker, MI, USA); Theraskin and Dermacell (LifeNet Health, VA, USA); FlexHD\/AllopatchHD and Amnioband (MTF Biologics, NJ, USA); Grafix\/Stravix (Smith + Nephew, MA, USA); Epicord and Epifix (MiMedx, GA, USA); Affinity, Apligraf and Dermagraft (Organogenesis, MA, USA)]). Patient demographics, comorbidities and ulcer location were assessed for cohort homogeneity and balanced via inverse probability of treatment weighting, to adjust for potential confounding factors when comparing health outcomes.\n                    <jats:bold>Results:<\/jats:bold>\n                    There were 940,910 patients with a DFU diagnosis; of these, 738,124 (78.4%) also had same-day diagnosis of a non-pressure chronic ulcer. After application of eligibility criteria, there were a total of 34,664 patients with DFUs with 37,380 episodes of care that included one of the CAMP treatments (PPECM: number of patients (n)\u00a0=\u00a0186, number of episodes (e)\u00a0=\u00a0186; PPECM\u2019s 510(k) predicate: n\u00a0=\u00a0369, e\u00a0=\u00a0370; and OSC: n\u00a0=\u00a033,858, e\u00a0=\u00a036,559). In the inverse probability of treatment weighting-balanced model, patients with OSC episodes were 1.309-times more likely to undergo outpatient amputation than those with PPECM (95% CI: 1.251\u20131.371, p\u00a0&lt;\u00a00.0001). Bacteremia was 2.75-times more likely in OSC episodes than in PPECM episodes (95% CI: 2.471\u20133.053, p\u00a0&lt;\u00a00.0001). PPECM episodes had significantly fewer outpatient hospital visits compared with both OSC and PPECM\u2019s 510(k) predicate (5.84, 8.79 and 10.24, respectively, p\u00a0&lt;\u00a00.0001). There were no differences in physician office visits or hospital admissions.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    The findings suggest that PPECM performed clinically as well as or better than other well-established CAMPs. Notably, episodes of DFU care that involved PPECM were associated with significantly fewer outpatient amputations, fewer episodes of bacteremia, and fewer outpatient hospital visits. These data suggest that PPECM offers a clinically competitive treatment option for patients with DFUs.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0092","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T08:53:47Z","timestamp":1753433627000},"source":"Crossref","is-referenced-by-count":6,"title":["Comparative effectiveness of porcine placental extracellular matrix against other cellular, acellular and matrix-like products in diabetic foot ulcers from the Medicare database"],"prefix":"10.57264","volume":"14","author":[{"given":"Brad","family":"Marcinek","sequence":"first","affiliation":[{"name":"Convatec Technology Centre, Lexington, MA 02421, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Levinson","sequence":"additional","affiliation":[{"name":"Convatec Technology Centre, Lexington, MA 02421, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Nally","sequence":"additional","affiliation":[{"name":"Convatec Technology Centre, Lexington, MA 02421, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5795-2576","authenticated-orcid":false,"given":"Irene","family":"Varghese","sequence":"additional","affiliation":[{"name":"ADVI Health LLC., Washington, DC 20004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5332-8832","authenticated-orcid":false,"given":"Caitlin","family":"Sheetz","sequence":"additional","affiliation":[{"name":"ADVI Health LLC., Washington, DC 20004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5535-4709","authenticated-orcid":false,"given":"Peter","family":"Kardel","sequence":"additional","affiliation":[{"name":"ADVI Health LLC., Washington, DC 20004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8084-8818","authenticated-orcid":false,"given":"Cristin","family":"Taylor","sequence":"additional","affiliation":[{"name":"Convatec Technology Centre, Lexington, MA 02421, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_9_3_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2337\/dci22-0043","article-title":"Etiology, epidemiology, and disparities in the burden of diabetic foot ulcers","volume":"46","author":"McDermott K","year":"2023","unstructured":"McDermott K, Fang M, Boulton AJM, Selvin E, Hicks CW. Etiology, epidemiology, and disparities in the burden of diabetic foot ulcers. Diabetes Care 46(1), 209\u2013221 (2023).","journal-title":"Diabetes Care"},{"issue":"3","key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/wound.2017.0743","article-title":"Publicly reported wound healing rates: the fantasy and the reality","volume":"7","author":"Fife CE","year":"2018","unstructured":"Fife CE, Eckert KA, Carter MJ. Publicly reported wound healing rates: the fantasy and the reality. Adv. Wound Care 7(3), 77\u201394 (2018).","journal-title":"Adv. Wound Care"},{"issue":"1","key":"e_1_3_9_5_2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jama.2023.10578","article-title":"Diabetic foot ulcers: a review","volume":"330","author":"Armstrong DG","year":"2023","unstructured":"Armstrong DG, Tan TW, Boulton AJM, Bus SA. Diabetic foot ulcers: a review. JAMA 330(1), 62\u201375 (2023).","journal-title":"JAMA"},{"issue":"1","key":"e_1_3_9_6_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/dom.14840","article-title":"Global mortality of diabetic foot ulcer: a systematic review and meta-analysis of observational studies","volume":"25","author":"Chen L","year":"2023","unstructured":"Chen L, Sun S, Gao Y, Ran X. Global mortality of diabetic foot ulcer: a systematic review and meta-analysis of observational studies. Diabetes Obes. Metab. 25(1), 36\u201345 (2023).","journal-title":"Diabetes Obes. Metab."},{"key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"655902","DOI":"10.3389\/fsurg.2021.655902","article-title":"Major amputation profoundly increases mortality in patients with diabetic foot infection","volume":"8","author":"Vuorlaakso M","year":"2021","unstructured":"Vuorlaakso M, Kiiski J, Salonen T, Karppelin M, Helminen M, Kaartinen I. Major amputation profoundly increases mortality in patients with diabetic foot infection. Front. Surg. 8, 655902 (2021).","journal-title":"Front. Surg."},{"issue":"1","key":"e_1_3_9_8_2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2337\/dc18-1380","article-title":"Resurgence of diabetes-related nontraumatic lower-extremity amputation in the young and middle-aged adult U.S. population","volume":"42","author":"Geiss LS","year":"2019","unstructured":"Geiss LS, Li Y, Hora I, Albright A, Rolka D, Gregg EW. Resurgence of diabetes-related nontraumatic lower-extremity amputation in the young and middle-aged adult U.S. population. Diabetes Care 42(1), 50\u201354 (2019).","journal-title":"Diabetes Care"},{"issue":"10","key":"e_1_3_9_9_2","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.2337\/dc20-0586","article-title":"National and state-level trends in nontraumatic lower-extremity amputation among U.S. Medicare beneficiaries with diabetes, 2000\u20132017","volume":"43","author":"Harding JL","year":"2020","unstructured":"Harding JL, Andes LJ, Rolka DB National and state-level trends in nontraumatic lower-extremity amputation among U.S. Medicare beneficiaries with diabetes, 2000\u20132017. Diabetes Care 43(10), 2453\u20132459 (2020).","journal-title":"Diabetes Care"},{"issue":"8","key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"107960","DOI":"10.1016\/j.jdiacomp.2021.107960","article-title":"Patient perspectives on the physical, psycho-social, and financial impacts of diabetic foot ulceration and amputation","volume":"35","author":"Crocker RM","year":"2021","unstructured":"Crocker RM, Palmer KNB, Marrero DG, Tan TW. Patient perspectives on the physical, psycho-social, and financial impacts of diabetic foot ulceration and amputation. J. Diabetes Complications 35(8), 107960 (2021).","journal-title":"J. Diabetes Complications"},{"issue":"8","key":"e_1_3_9_11_2","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.2337\/diacare.21.8.1240","article-title":"Potential economic benefits of lower-extremity amputation prevention strategies in diabetes","volume":"21","author":"Ollendorf DA","year":"1998","unstructured":"Ollendorf DA, Kotsanos JG, Wishner WJ Potential economic benefits of lower-extremity amputation prevention strategies in diabetes. Diabetes Care 21(8), 1240\u20131245 (1998).","journal-title":"Diabetes Care"},{"issue":"2","key":"e_1_3_9_12_2","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1086\/383275","article-title":"Health-economic consequences of diabetic foot lesions","volume":"39","author":"Tennvall RG","year":"2004","unstructured":"Tennvall RG, Apelqvist J. Health-economic consequences of diabetic foot lesions. Clin. Infect. Dis. 39(Suppl. 2), S132\u2013S139 (2004).","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"e_1_3_9_13_2","doi-asserted-by":"crossref","first-page":"S289","DOI":"10.1097\/PRS.0b013e3181fbe2a6","article-title":"The economics of limb salvage in diabetes","volume":"127","author":"Hunt NA","year":"2011","unstructured":"Hunt NA, Liu GT, Lavery LA. The economics of limb salvage in diabetes. Plast. Reconstr. Surg. 127(Suppl. 1), S289\u2013S295 (2011).","journal-title":"Plast. Reconstr. Surg."},{"issue":"8","key":"e_1_3_9_14_2","doi-asserted-by":"crossref","first-page":"e0134914","DOI":"10.1371\/journal.pone.0134914","article-title":"A Diabetic Emergency One Million Feet Long: Disparities and Burdens of Illness among Diabetic Foot Ulcer Cases within Emergency Departments in the United States, 2006\u20132010","volume":"10","author":"Skrepnek GH","year":"2015","unstructured":"Skrepnek GH, Mills JL Sr, Armstrong DG. A Diabetic Emergency One Million Feet Long: Disparities and Burdens of Illness among Diabetic Foot Ulcer Cases within Emergency Departments in the United States, 2006\u20132010. PLOS ONE 10(8), e0134914 (2015).","journal-title":"PLOS ONE"},{"issue":"10","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.2337\/diacare.25.10.1835","article-title":"Diabetic neuropathic foot ulcers: the association of wound size, wound duration, and wound grade on healing","volume":"25","author":"Margolis DJ","year":"2002","unstructured":"Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetic neuropathic foot ulcers: the association of wound size, wound duration, and wound grade on healing. Diabetes Care 25(10), 1835\u20131839 (2002).","journal-title":"Diabetes Care"},{"issue":"6","key":"e_1_3_9_16_2","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/dc05-2425","article-title":"Risk factors for foot infections in individuals with diabetes","volume":"29","author":"Lavery LA","year":"2006","unstructured":"Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabetes Care 29(6), 1288\u20131293 (2006).","journal-title":"Diabetes Care"},{"issue":"5","key":"e_1_3_9_17_2","doi-asserted-by":"crossref","first-page":"e0177916","DOI":"10.1371\/journal.pone.0177916","article-title":"Incidence and risk factors for developing infection in patients presenting with uninfected diabetic foot ulcers","volume":"12","author":"Jia L","year":"2017","unstructured":"Jia L, Parker CN, Parker TJ Incidence and risk factors for developing infection in patients presenting with uninfected diabetic foot ulcers. PLoS One 12(5), e0177916 (2017).","journal-title":"PLoS One"},{"issue":"6","key":"e_1_3_9_18_2","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/iwj.12788","article-title":"Risk factors for amputation in patients with diabetic foot infection: a prospective study","volume":"14","author":"Uysal S","year":"2017","unstructured":"Uysal S, Arda B, Ta\u015fbakan MI Risk factors for amputation in patients with diabetic foot infection: a prospective study. Int. Wound J. 14(6), 1219\u20131224 (2017).","journal-title":"Int. Wound J."},{"key":"e_1_3_9_19_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13047-019-0345-y","article-title":"Predictors of lower extremity amputation in patients with diabetic foot ulcer: findings from MEDFUN, a multi-center observational study","volume":"12","author":"Ugwu E","year":"2019","unstructured":"Ugwu E, Adeleye O, Gezawa I, Okpe I, Enamino M, Ezeani I. Predictors of lower extremity amputation in patients with diabetic foot ulcer: findings from MEDFUN, a multi-center observational study. J. Foot Ankle Res. 12, 1\u20138 (2019).","journal-title":"J. Foot Ankle Res."},{"issue":"1","key":"e_1_3_9_20_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.17219\/acem\/163240","article-title":"Assessment of the risk factors determining the prognosis of major and minor limb amputations in patients with diabetic foot ulcers","volume":"33","author":"Okur KT","year":"2024","unstructured":"Okur KT, Ozan F, Kahraman M, Melez M, \u00dcnl\u00fc \u00d6C, Altun \u0130. Assessment of the risk factors determining the prognosis of major and minor limb amputations in patients with diabetic foot ulcers. Adv. Clin. Exp. Med. 33(1), 21\u201330 (2024).","journal-title":"Adv. Clin. Exp. Med."},{"issue":"4","key":"e_1_3_9_21_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.12968\/jowc.2023.32.Sup4b.S1","article-title":"Best practice for wound repair and regeneration use of cellular, acellular and matrix-like products (CAMPs)","volume":"32","author":"Wu S","year":"2023","unstructured":"Wu S, Carter M, Cole W Best practice for wound repair and regeneration use of cellular, acellular and matrix-like products (CAMPs). J. Wound Care. 32(Sup4b), S1\u2013S31 (2023).","journal-title":"J. Wound Care."},{"key":"e_1_3_9_22_2","first-page":"1","article-title":"Effectiveness of most common adjuvant wound treatments (skin substitutes, negative pressure wound therapy, hyperbaric oxygen therapy, platelet-rich plasma\/fibrin, and growth factors) for the management of hard-to-heal diabetic foot ulcers: a meta-analysis of randomized controlled trials for the development of the Italian Guidelines for the Treatment of Diabetic Foot Syndrome","author":"Monami M","year":"2024","unstructured":"Monami M, Scatena A, Ragghianti B Effectiveness of most common adjuvant wound treatments (skin substitutes, negative pressure wound therapy, hyperbaric oxygen therapy, platelet-rich plasma\/fibrin, and growth factors) for the management of hard-to-heal diabetic foot ulcers: a meta-analysis of randomized controlled trials for the development of the Italian Guidelines for the Treatment of Diabetic Foot Syndrome. Acta Diabetol. 1\u201315 (2024).","journal-title":"Acta Diabetol."},{"issue":"12","key":"e_1_3_9_23_2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1089\/wound.2023.0075","article-title":"Systematic Review of Cellular, Acellular, and Matrix-like Products and Indirect Treatment Comparison Between Cellular\/Acellular and Amniotic\/Nonamniotic Grafts in the Management of Diabetic Foot Ulcers","volume":"13","author":"Banerjee J","year":"2024","unstructured":"Banerjee J, Lasiter A, Nherera L. Systematic Review of Cellular, Acellular, and Matrix-like Products and Indirect Treatment Comparison Between Cellular\/Acellular and Amniotic\/Nonamniotic Grafts in the Management of Diabetic Foot Ulcers. Adv. Wound Care 13(12), 639\u2013651 (2024).","journal-title":"Adv. Wound Care"},{"issue":"12","key":"e_1_3_9_24_2","first-page":"e76262","article-title":"Real-World Use and Outcomes of Hard-To-Heal Wounds Managed With Porcine Placental Extracellular Matrix","volume":"16","author":"Fife C","year":"2024","unstructured":"Fife C, LeBoutillier B, Taylor C, Marcinek BT. Real-World Use and Outcomes of Hard-To-Heal Wounds Managed With Porcine Placental Extracellular Matrix. Cureus 16(12), e76262 (2024).","journal-title":"Cureus"},{"issue":"7","key":"e_1_3_9_25_2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.12968\/jowc.2021.30.Sup7.S5","article-title":"Observed impact of skin substitutes in lower extremity diabetic ulcers: lessons from the Medicare Database (2015\u20132018)","volume":"30","author":"Armstrong DG","year":"2021","unstructured":"Armstrong DG, Tettelbach WH, Chang TJ Observed impact of skin substitutes in lower extremity diabetic ulcers: lessons from the Medicare Database (2015\u20132018). J. Wound Care 30(Sup7), S5\u2013S16 (2021).","journal-title":"J. Wound Care"},{"issue":"11","key":"e_1_3_9_26_2","doi-asserted-by":"crossref","first-page":"704","DOI":"10.12968\/jowc.2023.32.11.704","article-title":"Treatment patterns and outcomes of Medicare enrolees who developed venous leg ulcers","volume":"32","author":"Tettelbach WH","year":"2023","unstructured":"Tettelbach WH, Driver V, Oropallo A Treatment patterns and outcomes of Medicare enrolees who developed venous leg ulcers. J. Wound Care 32(11), 704\u2013718 (2023).","journal-title":"J. Wound Care"},{"issue":"1","key":"e_1_3_9_27_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye NC","year":"2022","unstructured":"Chesnaye NC, Stel VS, Tripepi G An introduction to inverse probability of treatment weighting in observational research. Clin. Kidney J. 15(1), 14\u201320 (2022).","journal-title":"Clin. Kidney J."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T08:54:06Z","timestamp":1756457646000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.57264\/cer-2025-0092"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0092","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"e250092"}}